Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SMMT

Summit Therapeutics Inc

Nov 03 • 01:36PM ET

18.51

-0.40 -2.11 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD NBIX ALNY BIIB AMGN SRPT AKTX PRTA

| Held by: XBI VTI VB VBR VXF IWP IBB VHT IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	86.96%	Shs Outstand	744.44M	Perf Week	-4.87%
Market Cap	13.75B	Forward P/E	-	EPS next Y	-0.89	Insider Trans	0.20%	Shs Float	96.87M	Perf Month	-13.62%
Enterprise Value	13.51B	PEG	-	EPS next Q	-0.22	Inst Own	13.34%	Short Float	33.32%	Perf Quarter	-36.45%
Income	-921.61M	P/S	-	EPS this Y	-338.58%	Inst Trans	0.12%	Short Ratio	7.93	Perf Half Y	-33.93%
Sales	0.00M	P/B	71.68	EPS next Y	34.31%	ROA	-241.08%	Short Interest	32.27M	Perf YTD	3.73%
Book/sh	0.26	P/C	57.55	EPS next 5Y	-	ROE	-292.49%	52W High	36.91 -49.85%	Perf Year	-0.74%
Cash/sh	0.32	P/FCF	-	EPS past 3/5Y	31.56% -10.52%	ROIC	-472.69%	52W Low	15.55 19.05%	Perf 3Y	1552.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.03% 6.80%	Perf 5Y	455.90%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-348.63%	Oper. Margin	-	ATR (14)	1.29	Perf 10Y	56.88%
Dividend Ex-Date	-	Quick Ratio	3.80	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.19	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	3.80	EPS Q/Q	-302.84%	SMA20	-9.54%	Beta	-1.22	Target Price	32.07
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-11.51%	Rel Volume	0.48	Prev Close	18.91
Employees	159	LT Debt/Eq	0.01	Earnings	Oct 20 BMO	SMA200	-17.43%	Avg Volume	4.07M	Price	18.51
IPO	Mar 05, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-82.25% -	Trades		Volume	1,262,765	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Initiated	Barclays	Underweight	$13
Sep-04-25	Initiated	Guggenheim	Buy	$40
Aug-19-25	Initiated	Piper Sandler	Neutral	$21
Jul-01-25	Initiated	UBS	Buy	$30
Jun-11-25	Initiated	Leerink Partners	Underperform	$12
Mar-26-25	Upgrade	Citigroup	Neutral → Buy	$23 → $35
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform	$30
Feb-28-25	Initiated	Goldman	Buy	$42
Jan-08-25	Initiated	Truist	Buy	$35
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31
Nov-04-24	Initiated	JMP Securities	Mkt Outperform	$32
Sep-27-24	Downgrade	Citigroup	Buy → Neutral	$19 → $23
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy	$30 → $27

Show Previous Ratings

Oct-31-25 07:07AM	Insiders Are Snapping Up These 2 Stocks and Analysts Like What They See (TipRanks)
07:00AM	Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 (Business Wire)
Oct-30-25 09:39PM	Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 (Insider Monkey)
Oct-28-25 06:43PM	Why Wall Street Is Backing These 3 Comeback Stocks (MarketBeat)
03:21PM	Insiders Are Buying These 3 Stocks Hand Over Fist (24/7 Wall St.)
12:37PM	Loading…
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
Oct-27-25 05:51AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-25-25 09:45AM	Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech (24/7 Wall St.)
Oct-24-25 07:00PM	Summit Therapeutics: A Risky Bet in the Biotech Arena? (Motley Fool)
04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks) -6.46%
09:24AM	Company News for Oct 21, 2025 (Zacks)
05:53AM	Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab (Insider Monkey)
Oct-20-25 03:00PM	Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com)
06:45AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 (Business Wire)
05:13AM	Loading…
05:13AM	Summits dual-acting drug scores lung cancer win (BioPharma Dive)
Oct-19-25 10:30AM	Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China (Business Wire)
07:33AM	Tesla, Netflix set to report earnings as US-China trade fight turns 'unsustainable': What to watch this week (Yahoo Finance)
Oct-17-25 07:00AM	Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer (Business Wire)
Oct-15-25 07:00AM	Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 (Business Wire)
Oct-08-25 12:57AM	Where is Summit Therapeutics (SMMT) Headed According to Analysts? (Insider Monkey)
Oct-07-25 08:27AM	Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock? (Zacks)
Oct-05-25 09:45AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-02-25 01:35AM	H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones (Insider Monkey)
Oct-01-25 01:39PM	Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 (Insider Monkey)
Sep-24-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.05%
07:00AM	HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 (Business Wire)
Sep-22-25 10:21AM	Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds? (Zacks)
Sep-18-25 11:25PM	Jim Cramer on Summit Therapeutics: "We're Going to Have to Move On" (Insider Monkey) +6.30%
10:41AM	Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China (Insider Monkey)
07:57PM	Loading…
Sep-12-25 07:57PM	Lightning Round: Ring the register on Opendoor, don't be in a meme stock, says Jim Cramer (CNBC TV)
Sep-11-25 10:05AM	Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock? (Zacks) +5.65%
Sep-10-25 12:59AM	Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating (Insider Monkey) -6.48%
Sep-09-25 01:17PM	SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study (Zacks)
05:58AM	S&P Futures Tick Higher Ahead of U.S. Payrolls Revisions (Barchart)
05:51AM	Is Summit Therapeutics a Buy, Sell, or Hold Now? (Motley Fool)
Sep-08-25 06:12PM	Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health (TheStreet) -25.15%
04:08PM	Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch (Investor's Business Daily)
11:26AM	Stock Market Today: Stocks rise as investors embrace supersized cut chances (TheStreet)
09:33AM	Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics (Yahoo Finance Video)
08:28AM	Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences (Benzinga)
07:53AM	New Summit data clouds approval pathway in lung cancer (BioPharma Dive)
Sep-07-25 03:30AM	Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC (Business Wire)
Sep-05-25 09:35AM	Apple upgraded, AMD downgraded: Wall Streets top analyst calls (TipRanks) +9.16%
Sep-04-25 09:33AM	Apple upgraded, AMD downgraded: Wall Street's top analyst calls (The Fly)
Sep-03-25 07:00AM	Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025 (Business Wire)
Aug-31-25 06:45AM	3 No-Brainer Stocks to Buy Right Now (Motley Fool)
12:10AM	H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44 (Insider Monkey)
Aug-27-25 08:07AM	Stock Market Today: Stocks rise ahead of Nvidia's after hour earnings (TheStreet) -8.06%
Aug-19-25 09:06AM	Can Keytruda Sustain Merck's Growth Through the Rest of 2025? (Zacks)
Aug-18-25 11:43PM	Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism (Insider Monkey)
Aug-17-25 06:42AM	3 Fantastic Growth Stocks to Buy in August (Motley Fool)
Aug-14-25 07:00AM	Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 (Business Wire)
Aug-13-25 12:49PM	Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call (Insider Monkey)
Aug-12-25 11:43AM	SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus (Zacks) -9.08%
Aug-11-25 05:03PM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 (Business Wire)
09:17AM	Merck Stock Down 4% Since Q2 Results: How to Play the Stock (Zacks)
Jul-28-25 04:00AM	Could bispecifics unseat Keytruda from its oncology throne? (Pharma Voice)
Jul-25-25 08:27AM	Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results? (Zacks)
Jul-22-25 04:14AM	3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results (Motley Fool)
Jul-21-25 10:00AM	This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich (Motley Fool)
12:07AM	3 Monster Stocks in the Making to Buy Right Now (Motley Fool)
Jul-17-25 03:55PM	Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings (Insider Monkey)
Jul-14-25 11:08AM	Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits? (Zacks)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
Jul-11-25 08:19AM	Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? (Zacks)
Jul-10-25 08:53AM	Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal (Insider Monkey)
Jul-07-25 08:52AM	SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca (Zacks) -7.90%
Jul-06-25 04:01AM	Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug (Insider Monkey)
04:00AM	Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors (Insider Monkey)
Jul-04-25 08:15AM	2 Soaring Stocks With More Upside Potential to Buy and Hold (Motley Fool)
Jul-03-25 06:26PM	Why AstraZeneca Stock Got Thumped on Thursday (Motley Fool) +8.53% -7.90%
03:50PM	Why Summit Therapeutics Stock Soared 8% Higher Today (Motley Fool)
01:56PM	Lucid, Alibaba, AstraZeneca & Summit: Trending Tickers (Yahoo Finance Video)
12:54PM	Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks (Investopedia)
10:58AM	Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal (Investing.com)
10:38AM	Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports (Reuters)
Jul-02-25 09:55AM	Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade (Zacks) +6.70%
02:47AM	Summit Therapeutics (SMMT) Rated Buy on Ivonescimab's Cancer-Fighting Potential (Insider Monkey)
Jun-30-25 08:00AM	Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors (Business Wire)
Jun-25-25 06:30PM	H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target (Insider Monkey)
09:59AM	Merck Moves Past 50-Day Average: How to Play MRK Stock Now (Zacks)
Jun-11-25 05:28PM	Why Summit Therapeutics Stock Tanked Today (Motley Fool) -11.32%
Jun-10-25 09:46AM	Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE? (Zacks)
Jun-09-25 10:18AM	Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip? (Zacks)
Jun-06-25 04:44PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
05:52AM	Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday (Insider Monkey)
03:19AM	2 Soaring Stocks Wth More Upside Potential (Motley Fool)
Jun-04-25 07:26AM	Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday (Insider Monkey) -5.14%
Jun-03-25 09:35AM	Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround (Zacks) +16.33%
Jun-02-25 11:46AM	Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks)
11:39AM	Bristol Myers Joins Pharma's Hottest Horserace in $11.1B Deal With BioNTech (Barrons.com)
08:07AM	Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal (Bloomberg)
07:00AM	3 No-Brainer Healthcare Stocks to Buy in June (Motley Fool)
05:23AM	Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? (Motley Fool)
May-30-25 02:19PM	Why Summit Therapeutics Plunged Today (Motley Fool) -30.50%
09:27AM	Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. (Barrons.com)
09:22AM	Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure (Investor's Business Daily)
06:50AM	New Summit data could slow US approval plans for PD-1/VEGF drug (BioPharma Dive)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xia Yu	Director	Oct 21 '25	Buy	18.74	533,617	9,999,983	32,057,147	Oct 23 09:06 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:08 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:06 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:36 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:36 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:32 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:32 PM
Zanganeh Mahkam	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 05:01 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience